Although 2021 marks the centenary of insulin's discovery, insulin access remains a global health issue.
Insulin aspart, lispro, and glargine biosimilar candidates referencing NovoRapid, Humalog, and Lantus demonstrated bioequivalence in trial data presented at the Scientific Sessions of the American Diabetes Association.
Gan & Lee Pharmaceuticals said positive phase 1 clinical results were achieved for 3 insulin analog biosimilar candidates: insulin aspart (GL-ASP), insulin lispro (GL-LIS), and insulin glargine (GL-GLA), referencing NovoRapid, Humalog, and Lantus, respectively.
Although 2021 marks the centenary of insulin's discovery, insulin access remains a global health issue.
The results were presented at Scientific Sessions of the American Diabetes Association, held June 25-29, 2021. The company said all 3 studies met their primary pharmacokinetic (PK) and pharmacodynamic (PD) end points.
“These data demonstrate PK and PD bioequivalence between each of the proposed biosimilar Gan & Lee insulins and their respective reference compounds. In addition, the safety profiles were comparable,” according to a company statement.
Currently, there are no insulin biosimilars available in the United States, although the second half of 2021 is expected to produce at least 2 approvals.
Proposed Insulin Aspart Biosimilar
The trial of GL-ASP enrolled 36 health male volunteers who each received a single dose of either the biosimilar candidate or the US or EU versions of NovoRapid (rapid acting) in each of the 3 euglycemic glucose “clamp” periods. The clamp technique maintains blood glucose concentrations at predefined target levels to allow assessments of insulin action.
Investigators said the aspart concentration and glucose infusion rate profiles between products were “superimposable” in terms of comparability. PK biosimilarity was demonstrated in terms of serum aspart concentration, and primary PD end points and sensitivity analyses also demonstrated equivalence.
They said adverse events (AEs) were rare with just 7 to 14 AEs per insulin and just 1 injection site reaction with GL-ASP (mild erythema).
Proposed Insulin Lispro Biosimilar
A randomized, double-blind crossover trial compared PK and PD properties of GL-LIS with the US and EU versions of Humalog, a fast-acting insulin, in 38 healthy male volunteers.
Investigators said each participant received a single 0.2 U/kg dose of 1 the 3 formulations in each of the 3 euglycemic glucose clamp periods. Serum lispro concentration and glucose infusion rate profiles were “superimposable, demonstrating biosimilarity, they said.
Serum lispro concentration point estimates were close to 100% between the biosimilar candidate and the reference versions, and the 90% CIs were within predefined similarity margins of 80% to 125%. Primary PD and secondary PK/PD end points met biosimilarity criteria, as did sensitivity analyses.
Investigators reported a low incidence of AEs (5-11 AEs per insulin). There were no injection site reactions.
Proposed Insulin Glargine Biosimilar
A randomized, double-blind crossover trial of GL-GLA vs the US and EU versions of Lantus (glargine, long acting) was conducted in 114 healthy male volunteers with type 1 diabetes. Participants received a single dose (0.5 U/kg) of GL-GLA or the US or EU versions of Lantus in each of the 3 euglycemic glucose clamp periods.
Investigators said the PK and glucose infusion rates were “superimposable,” point estimates for measured metabolite M1 were close to 100%, and the 90% CIs were well within the predefined similarity margins of 80% to 125%.
They said the primary and secondary PK/PD end points were met and all insulins were well tolerated with matching AE rates of 19%, 26% and 21% for GL-GLA, and the US and EU formulations of Lantus, respectively. There were few injection site reactions per insulin.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
The 6 Key Policy Factors to Ensure Biosimilar Market Sustainability
April 16th 2024Magnus Bodin, senior director and head of international access and policy at Biogen, presented warning signs for unsustainable biosimilar markets as well as key factors needed to create effective policies and future-proof biosimilar markets globally.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.